Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


11.08.2025

1 AJR Am J Roentgenol
2 Anticancer Res
2 BJU Int
1 BMC Cancer
2 BMC Urol
3 Cancer
2 Cancer Res
4 Eur Radiol
2 Eur Urol
1 Int J Oncol
2 Int J Urol
1 J Clin Oncol
3 J Nucl Med
1 Lancet Oncol
1 N Engl J Med
1 Nat Rev Urol
3 Oncogene
1 PLoS Comput Biol
1 Urol Int
2 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. ABREU-GOMEZ J
    Artificial Intelligence-Assisted MRI Interpretation in Prostate Cancer: Supporting Confidence and Reducing Variability.
    AJR Am J Roentgenol. 2025 Aug 6. doi: 10.2214/AJR.25.33622.
    PubMed        


    Anticancer Res

  2. HATTORI A, Seki T, Kato K, Virgona N, et al
    NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway.
    Anticancer Res. 2025;45:3197-3207.
    PubMed         Abstract available

  3. BABU YSR, Venkatachalam KV
    Methionine Deprivation-induced Cancer Cell Death and Methylation Changes in Key Genes and Gene Promoters of Prostate Cancer Cell Lines.
    Anticancer Res. 2025;45:3209-3219.
    PubMed         Abstract available


    BJU Int

  4. OLIVIER J, Vertosick E, Delobel L, Bommelaere T, et al
    Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16884.
    PubMed         Abstract available

  5. SANAPALA K, Mehta R, Sah R
    Comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 2. doi: 10.1111/bju.16868.
    PubMed        


    BMC Cancer

  6. AHAMED Y, Hossain M, Baral S, Al-Raiyan AU, et al
    The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.
    BMC Cancer. 2025;25:1264.
    PubMed         Abstract available


    BMC Urol

  7. DINC SC, Ucgul AN, Bora H, Senturk E, et al
    The dosimetric impacts of ct-based deep learning autocontouring algorithm for prostate cancer radiotherapy planning dosimetric accuracy of DirectORGANS.
    BMC Urol. 2025;25:190.
    PubMed         Abstract available

  8. SUN J, Song Y, Tan Y, Ma L, et al
    Predictive value of inflammatory marker PLR in prostate cancer.
    BMC Urol. 2025;25:188.
    PubMed         Abstract available


    Cancer

  9. TSUNG I, Yentz SE, Reichert ZR
    Controversies in metastatic hormone-sensitive prostate cancer.
    Cancer. 2025;131:e70030.
    PubMed         Abstract available

  10. NORIEGA ESQUIVES BS, Manoharan A, Penedo FJ, Dee EC, et al
    Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos.
    Cancer. 2025;131:e70029.
    PubMed         Abstract available

  11. NIERENGARTEN MB
    Superior prostate cancer detection with LATP versus TRUS.
    Cancer. 2025;131:e35958.
    PubMed        


    Cancer Res

  12. CORDOVA RA, Elbanna M, Rupert C, Orsi SA, et al
    Caloric Restriction Enhances the Efficacy of Anti-Androgen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
    Cancer Res. 2025 Aug 8. doi: 10.1158/0008-5472.CAN-24-1986.
    PubMed         Abstract available

  13. MA S, Ge Y, Lu Z, Zhang J, et al
    Integrated Omics and Multi-Cohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer.
    Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-5018.
    PubMed         Abstract available


    Eur Radiol

  14. JOHNSON PM, Tong A, Ginocchio L, Del Hoyo JL, et al
    External evaluation of an open-source deep learning model for prostate cancer detection on bi-parametric MRI.
    Eur Radiol. 2025 Aug 3. doi: 10.1007/s00330-025-11865.
    PubMed         Abstract available

  15. KEIVANY MR, Zare H
    Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11896.
    PubMed        

  16. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11897.
    PubMed        

  17. THORLEY N, Parry T, Giganti F, Kopcke D, et al
    Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11837.
    PubMed         Abstract available


    Eur Urol

  18. SHERRY AD, Siddiqui BA, Haymaker C, Fellman BM, et al
    Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
    Eur Urol. 2025 Jul 31:S0302-2838(25)00396-3. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available

  19. HALABI S, Guo S, Luo B, Yu C, et al
    Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
    Eur Urol. 2025 Aug 6:S0302-2838(25)00407-5. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available


    Int J Oncol

  20. LONG Z, Chang Y, Zhu K, Chen Z, et al
    Cuproptosis in prostate cancer: Molecular mechanisms, prognostic biomarkers and therapeutic frontiers of cuproptosis?related genes (Review).
    Int J Oncol. 2025;67:77.
    PubMed         Abstract available


    Int J Urol

  21. TOHI Y, Kato T, Fujiwara K, Harada S, et al
    Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
    Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
    PubMed         Abstract available

  22. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
    Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
    Int J Urol. 2025;32:982-989.
    PubMed         Abstract available


    J Clin Oncol

  23. MENNE GURICOVA K, Draulans C, Pos FJ, Kerkmeijer LGW, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.
    J Clin Oncol. 2025 Aug 4:JCO2500274. doi: 10.1200/JCO-25-00274.
    PubMed         Abstract available


    J Nucl Med

  24. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    PubMed         Abstract available

  25. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    PubMed         Abstract available

  26. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    PubMed         Abstract available


    Lancet Oncol

  27. EMMETT L, Papa N, Subramaniam S, Crumbaker M, et al
    Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025 Jul 30:S1470-2045(25)00339.
    PubMed         Abstract available


    N Engl J Med


  28. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2025 Aug 1. doi: 10.1056/NEJMx250003.
    PubMed        


    Nat Rev Urol

  29. NI HM, Kouzy R, Sabbagh A, Rooney MK, et al
    The state of the art in artificial intelligence and digital pathology in prostate cancer.
    Nat Rev Urol. 2025 Aug 4. doi: 10.1038/s41585-025-01070.
    PubMed         Abstract available


    Oncogene

  30. SANCHIS P, Sabater A, Lechuga J, Rada J, et al
    PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression.
    Oncogene. 2025 Aug 2. doi: 10.1038/s41388-025-03511.
    PubMed         Abstract available

  31. HAO JL, He JQ, Hu H, Zhu ZH, et al
    TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity.
    Oncogene. 2025 Aug 4. doi: 10.1038/s41388-025-03517.
    PubMed         Abstract available

  32. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03531.
    PubMed        


    PLoS Comput Biol

  33. GOLZARYAN A, Souri M, Kashkooli FM, Rahmim A, et al
    Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.
    PLoS Comput Biol. 2025;21:e1013247.
    PubMed         Abstract available


    Urol Int

  34. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    PubMed         Abstract available


    Urology

  35. MICHAEL JA, Greenberg DR, Ascha M, Gonzales-Alabastro CD, et al
    Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Nonbinary Patients: Retrospective Review of a Single-Institution Experience.
    Urology. 2025 Jul 31:S0090-4295(25)00735-6. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available

  36. KARWACKI J, Wojdylo L, Klasen K, Dlubak A, et al
    Reply to Letter to the Editor on "Revisiting the Role of Lymphovascular Invasion in Prostate Cancer: A Narrative Review".
    Urology. 2025 Aug 1:S0090-4295(25)00750-2. doi: 10.1016/j.urology.2025.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.